Bispecific therapy clinical trial for oncology patients starts in February

See quick reference tipsheet

Oregon Oncology Specialists (OOS) will begin a clinical trial in February that uses a new cancer treatment called Bispecific Antibody Therapy.

Patients eligible for this trial may present to the Salem Hospital emergency department and will need admission to the A7E Inpatient Oncology unit and/or Intensive Care unit, depending on the grading of two primary toxicities: CRS and ICANS, which also require specific treatment.

See quick reference sheet for providers, below.

For more information on this clinical trial or supporting these patients, please reach out to Oregon Oncology Specialists Ryan Cain, PA-C, at rcain@orcancer.com, or Julie Hinson, NP-C, at JHinson@orcancer.com.